Form 4: HealthEquity Director Selander Exercises Options and Sells Shares Under 10b5-1 Plan

Sentiment:

SEC Form 4 Filing


Robert W. Selander, a director at HealthEquity, Inc., executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

  • On April 9, 2025, Robert W. Selander, a director of HealthEquity, Inc., exercised stock options to acquire 12,500 shares of common stock at a price of $28.68 per share.
  • Simultaneously, Selander sold a total of 5,750 shares of HealthEquity common stock in multiple transactions at weighted average prices of $76.7868, $78.0598, and $78.81.
  • These transactions were executed under a Rule 10b5-1 trading plan adopted on July 9, 2024.
  • Following these transactions, Selander directly owns 84,969 shares of HealthEquity common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about stock option exercises and share sales.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of HealthEquity's director, Robert W. Selander. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without concerns about insider trading, as the plan is established in advance.

Comparison to Industry Standards

  • Insider trading activity is a common occurrence in publicly traded companies.
  • Form 4 filings are standard practice and are used to ensure transparency in the market.
  • The use of 10b5-1 trading plans is a widespread method for corporate insiders to manage their stock holdings while avoiding accusations of trading on non-public information.
  • Comparable companies such as Teladoc Health and Accolade also have frequent Form 4 filings related to stock option exercises and sales by their executives and directors.

Stakeholder Impact

  • The transactions may have a minor impact on shareholders due to the change in ownership.
  • The transactions are unlikely to significantly affect employees, customers, suppliers, or creditors.

Key Dates

DateDescription
June 26, 2023Power of Attorney given by Mr. Selander was previously filed with the U.S. Securities and Exchange Commission.
July 09, 2024Rule 10b5-1 trading plan adopted.
04/09/2025Date of earliest transaction: Stock option exercise and sale of common stock.
09/29/2025Expiration date of stock options.
04/11/2025Date of signature of the Form 4 filing.

Keywords

HealthEquity, HQY, Robert Selander, Form 4, Stock Options, Share Sales, Rule 10b5-1, Director, Insider Trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.